$CODX
Co-Diagnostics Inc Stock $codx

$codx Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222031350 Filed on November 10, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$1.401M	$5.094M	$30.10M
YoY Change	-93.13%	-83.08%	37.95%
Cost Of Revenue	$515.8K	$767.9K	$3.311M
YoY Change	-79.26%	-76.81%	-43.11%
Gross Profit	$885.7K	$4.327M	$26.79M
YoY Change	-95.06%	-83.85%	67.44%
Gross Profit Margin	63.2%	84.93%	89.0%
Selling, General & Admin	$6.580M	$5.512M	$7.173M
YoY Change	23.67%	-23.15%	139.09%
% of Gross Profit	742.95%	127.4%	26.77%
Research & Development	$4.739M	$5.037M	$5.893M
YoY Change	117.17%	-14.52%	540.58%
% of Gross Profit	535.1%	116.43%	22.0%
Depreciation & Amortization	$298.6K	$313.0K	$94.04K
YoY Change	191.05%	232.83%	213.47%
% of Gross Profit	33.72%	7.23%	0.35%
Operating Expenses	$11.62M	$10.86M	$13.16M
YoY Change	52.76%	-17.46%	232.32%
Operating Profit	-$10.73M	-$6.536M	$13.63M
YoY Change	-204.11%	-147.95%	13.21%
Interest Expense	$256.7K	$169.1K	-$53.56K
YoY Change	-1378.59%	-415.8%	-106.87%
% of Operating Profit			-0.39%
Other Income/Expense, Net		$3.060M	-$53.56K
YoY Change		-5812.95%
Pretax Income	-$25.04M	-$3.476M	$13.58M
YoY Change	-344.47%	-125.6%	5.9%
Income Tax	-$3.139M	-$2.115M	$2.101M
% Of Pretax Income			15.47%
Net Earnings	-$21.91M	-$1.361M	$11.48M
YoY Change	-392.13%	-111.86%	-27.04%
Net Earnings / Revenue	-1563.02%	-26.72%	38.12%
Basic Earnings Per Share		-$0.04	$0.40
Diluted Earnings Per Share	-$0.74	-$0.04	$383.1K
COMMON SHARES
Basic Shares Outstanding	30.92M shares	33.78M shares	28.94M shares
Diluted Shares Outstanding		31.32M shares	29.95M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$81.26M	$86.49M	$83.91M
YoY Change	-9.57%	3.08%	207.59%
Cash & Equivalents	$22.97M	$81.51M	$82.66M
Short-Term Investments	$58.29M	$4.982M	$1.251M
Other Short-Term Assets	$761.2K	$1.316M	$485.1K
YoY Change	-68.46%	171.31%	-85.26%
Inventory	$5.310M	$5.442M	$3.303M
Prepaid Expenses
Receivables	$3.454M	$7.962M	$14.59M
Other Receivables	$1.945M	$705.8K	$0.00
Total Short-Term Assets	$92.73M	$101.9M	$102.3M
YoY Change	-19.45%	-0.36%	96.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.539M	$2.438M	$1.525M
YoY Change	31.36%	59.9%	182.37%
Goodwill		$15.39M
YoY Change
Intangibles	$26.77M	$26.88M
YoY Change	-1.57%
Long-Term Investments	$672.7K	$748.7K	$1.034M
YoY Change	-33.06%	-27.6%	-52.35%
Other Assets			$512.5K
YoY Change
Total Long-Term Assets	$30.35M	$45.93M	$3.071M
YoY Change	-32.42%	1395.23%	13.76%
TOTAL ASSETS
Total Short-Term Assets	$92.73M	$101.9M	$102.3M
Total Long-Term Assets	$30.35M	$45.93M	$3.071M
Total Assets	$123.1M	$147.8M	$105.4M
YoY Change	-23.09%	40.32%	92.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$952.3K	$2.056M	$800.0K
YoY Change	56.76%	156.99%	220.0%
Accrued Expenses	$934.4K	$1.512M	$2.086M
YoY Change	-75.79%	-27.52%	129.2%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.873M	$6.012M	$4.120M
YoY Change	-69.25%	45.93%	127.62%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.275M	$3.086M	$1.080M
YoY Change	-60.32%	185.68%	1700.6%
Total Long-Term Liabilities	$4.693M	$6.883M	$1.080M
YoY Change	-63.79%	537.15%	1700.6%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.873M	$6.012M	$4.120M
Total Long-Term Liabilities	$4.693M	$6.883M	$1.080M
Total Liabilities	$8.566M	$12.90M	$5.200M
YoY Change	-66.48%	147.98%	178.09%
SHAREHOLDERS EQUITY
Retained Earnings	$39.93M	$61.84M
YoY Change	-26.28%
Common Stock	$34.75K	$34.33K
YoY Change	2.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$14.21M	$12.99M
YoY Change
Treasury Stock Shares	3.882M shares	3.414M shares
Shareholders Equity	$114.5M	$134.9M	$100.2M
YoY Change
Total Liabilities & Shareholders Equity	$123.1M	$147.8M	$105.4M
YoY Change	-23.09%	40.32%	92.79%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$21.91M	-$1.361M	$11.48M
YoY Change	-392.13%	-111.86%	-27.04%
Depreciation, Depletion And Amortization	$298.6K	$313.0K	$94.04K
YoY Change	191.05%	232.83%	213.47%
Cash From Operating Activities	-$4.010M	$1.118M	$11.51M
YoY Change	-182.19%	-90.28%	34.45%
INVESTING ACTIVITIES
Capital Expenditures	$293.3K	-$230.0K	-$165.7K
YoY Change	-340.9%	38.81%	65.73%
Acquisitions
YoY Change
Other Investing Activities	-$53.01M	$4.969M	$1.036M
YoY Change	-4546.48%	379.86%	-117.12%
Cash From Investing Activities	-$53.31M	$4.739M	$869.8K
YoY Change	-5079.58%	444.84%	-114.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$5.500K
YoY Change			-98.04%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.218M	-10.39M	5.500K
YoY Change		-189098.0%	-97.96%
NET CHANGE
Cash From Operating Activities	-4.010M	1.118M	11.51M
Cash From Investing Activities	-53.31M	4.739M	869.8K
Cash From Financing Activities	-1.218M	-10.39M	5.500K
Net Change In Cash	-58.53M	-4.537M	12.38M
YoY Change	-1083.94%	-136.64%	362.1%
FREE CASH FLOW
Cash From Operating Activities	-$4.010M	$1.118M	$11.51M
Capital Expenditures	$293.3K	-$230.0K	-$165.7K
Free Cash Flow	-$4.303M	$1.348M	$11.67M
YoY Change	-186.06%	-88.45%	34.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001692415
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable		usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2022Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent		usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2021Q3	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies		usd
	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies		usd
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies		usd
	CODX	Noncash Lease Expense NoncashLeaseExpense		usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
	us-gaap	Proceeds From Divestiture Of Interest In Joint Venture ProceedsFromDivestitureOfInterestInJointVenture		usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	CODX	Business Acquisition Measurement Period Adjustments BusinessAcquisitionMeasurementPeriodAdjustments		usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability		usd
CY2022Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Granted In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Granted Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsGrantedWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Expirations Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2114638	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1470058	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree		usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2022Q3	CODX	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour		usd
	dei	Entity File Number EntityFileNumber	001-38148
	dei	Entity Registrant Name EntityRegistrantName	CO-DIAGNOSTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	UT
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-2609396
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2401 S. Foothill Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite D
	dei	Entity Address City Or Town EntityAddressCityOrTown	Salt Lake City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84109
	dei	City Area Code CityAreaCode	(801)
	dei	Local Phone Number LocalPhoneNumber	438-1036
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	CODX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2055889	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	607506	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1511720	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3859652	usd
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30917856	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81507983	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	88607234	usd
CY2022Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4982350	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1255266	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7961664	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20839182	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	5441726	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	2004169	usd
CY2022Q3	us-gaap	Income Tax Receivable IncomeTaxReceivable	705849	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1241143	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2338444	usd
CY2022Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	75000	usd
CY2021Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	75000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	101915715	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	115119295	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2438112	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1933216	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	456251	usd
CY2022Q3	us-gaap	Goodwill Goodwill	15388546	usd
CY2021Q4	us-gaap	Goodwill Goodwill	14706818	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26875000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	27195000	usd
CY2022Q3	us-gaap	Real Estate Investments Joint Ventures RealEstateInvestmentsJointVentures	748737	usd
CY2021Q4	us-gaap	Real Estate Investments Joint Ventures RealEstateInvestmentsJointVentures	1004953	usd
CY2022Q3	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	18750	usd
CY2021Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	75000	usd
CY2022Q3	us-gaap	Assets Assets	147841111	usd
CY2021Q4	us-gaap	Assets Assets	160034282	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	292536	usd
CY2022Q3	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	2152064	usd
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	5767304	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	2213088	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	150000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6012209	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12597550	usd
CY2022Q3	CODX	Taxes Payable Noncurrent TaxesPayableNoncurrent	1559557	usd
CY2021Q4	CODX	Taxes Payable Noncurrent TaxesPayableNoncurrent	1067853	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	3797158	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	7228444	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	126280	usd
CY2022Q3	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	1400490	usd
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	4665337	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6883485	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	12961634	usd
CY2022Q3	us-gaap	Liabilities Liabilities	12895694	usd
CY2021Q4	us-gaap	Liabilities Liabilities	25559184	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34332182	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30917856	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33819862	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33819862	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	34332	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	33820	usd
CY2022Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	3414326	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2022Q3	us-gaap	Treasury Stock Value TreasuryStockValue	12994373	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	86068948	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	80271999	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	61836510	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	54169279	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	134945417	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	134475098	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	147841111	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	160034282	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5094456	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30101353	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32816726	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	77484262	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	767936	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7055666	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	3311255	usd
	us-gaap	Cost Of Revenue CostOfRevenue	4965319	usd
	us-gaap	Cost Of Revenue CostOfRevenue	9088175	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	4326520	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	26790098	usd
	us-gaap	Gross Profit GrossProfit	27851407	usd
	us-gaap	Gross Profit GrossProfit	68396087	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1889907	usd
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4253091	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6014280	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	11303950	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3622273	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2919498	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9012888	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8323620	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5037461	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5893350	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12698632	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12779573	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	312494	usd
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	94038	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	984100	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	232757	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	10862135	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	13159977	usd
	us-gaap	Operating Expenses OperatingExpenses	28709900	usd
	us-gaap	Operating Expenses OperatingExpenses	32639900	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6535615	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	13630121	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-858493	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	35756187	usd
CY2022Q3	us-gaap	Interest Income Other InterestIncomeOther	298184	usd
CY2021Q3	us-gaap	Interest Income Other InterestIncomeOther	11379	usd
	us-gaap	Interest Income Other InterestIncomeOther	371248	usd
	us-gaap	Interest Income Other InterestIncomeOther	36565	usd
CY2022Q3	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	4044	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-138117	usd
CY2022Q3	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	2886734	usd
	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	7079446	usd
CY2022Q3	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-129047	usd
CY2021Q3	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-64940	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-256911	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-401288	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3059915	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-53561	usd
	CODX	Noncash Lease Expense NoncashLeaseExpense	17193	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3851293	usd
	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	7079446	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-364723	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3475700	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	13576560	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6197173	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	35391464	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2114638	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2100594	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1470058	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6231310	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1361062	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	11475966	usd
	us-gaap	Net Income Loss NetIncomeLoss	7667231	usd
	us-gaap	Net Income Loss NetIncomeLoss	29160154	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.40
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.01
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.38
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.23
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.98
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31321368	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28941357	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32109213	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28800450	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31321368	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29952690	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33002539	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29872415	shares
	us-gaap	Net Income Loss NetIncomeLoss	7667231	usd
	us-gaap	Net Income Loss NetIncomeLoss	29160154	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	984100	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	232757	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5138815	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-256911	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-401288	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-138117	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3431286	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	34672	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	338057	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	156011	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-12539461	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2608777	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-441786	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	116068	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3656463	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4733200	usd
	CODX	Noncash Or Part Noncash Inventory Moved To Property Plant And Equipment NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment	218906	usd
	CODX	Noncash Or Part Noncash Inventory Moved To Property Plant And Equipment NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment	260216	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	681327	usd
	CODX	Business Acquisition Measurement Period Adjustments BusinessAcquisitionMeasurementPeriodAdjustments	681728	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	134475098	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	50001	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-4432048	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-150000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-115751	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1822977	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	692823	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-802955	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	82495	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10578544	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	36202945	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1134208	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	547708	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6223740	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	3084161	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	9950824	usd
	us-gaap	Proceeds From Divestiture Of Interest In Joint Venture ProceedsFromDivestitureOfInterestInJointVenture	491739	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4861292	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3028192	usd
	CODX	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	177870	usd
	CODX	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	450398	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	12994373	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-12816503	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	450398	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7099251	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	39681535	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	88607234	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	42976713	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	81507983	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	82658248	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4496239	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	100000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1375097	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	11714596	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	147714792	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	27869	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1533284	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	480776	usd
CY2022Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	2599478	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2686303	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	144470940	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2230434	usd
CY2022Q3	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	10394895	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1361062	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	134945417	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	66696509	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	148980	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1513012	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	7898975	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	76257476	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	295917	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	927337	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	9785213	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	87265943	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5500	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1410945	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	11475966	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	100158354	usd
CY2022Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	8969317	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1007653	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7961664	usd
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	21508779	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	669597	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20839182	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31321368	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28941357	shares
CY2022Q3	us-gaap	Inventory Net InventoryNet	5441726	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1283850	usd
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	4157876	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	2004169	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	983088	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1021081	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32109213	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28800450	shares
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5037461	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12698632	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5893350	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12779573	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zWcHqxotcVp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zjPNMSHWXKr">Concentrations Risk and Significant Customers</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had certain customers which are each responsible for generating <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zrksm1Yj4fH" title="Concentration risk percentage"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zymiHqVQEHrf" title="Concentration risk percentage">10</span></span>% or more of the total revenue for the three and nine months ended September 30, 2022. One customer accounted for approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8afH22KiXC4" title="Concentration risk percentage">52</span>% of total revenue for the three months ended September 30, 2022, and two customers together accounted for approximately <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zuunLnWeYD9k">47</span>% of total revenue for the nine months ended September 30, 2022. Two customers together accounted for approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210701__20210930__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zRoxBpq3U138" title="Concentration risk percentage">56</span>% of total revenue for the three months ended September 30, 2021, and three customers together accounted for approximately <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__srt--MajorCustomersAxis__custom--ThreeCustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zletOWVV8JD1" title="Concentration risk percentage">49</span>% of total revenue for the nine months ended September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Four customers accounted for more than <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--FourCustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zBMUkDmyPp4f" title="Concentration risk percentage">10</span>% of accounts receivable at September 30, 2022 and two customers accounted for more than <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zx570d13Xy2c" title="Concentration risk percentage">10</span>% of accounts receivable at December 31, 2021. These customers together accounted for approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z7CfdgXK9Q4i" title="Concentration risk percentage">67</span>% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zMEhppq67fGj" title="Concentration risk percentage">66</span>% of accounts receivable at September 30, 2022 and December 31, 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	CODX	Remeasurement Of Acquisition Contingencies RemeasurementOfAcquisitionContingencies	78617	usd
CY2021Q4	us-gaap	Goodwill Goodwill	14706818	usd
	us-gaap	Goodwill Translation And Purchase Accounting Adjustments GoodwillTranslationAndPurchaseAccountingAdjustments	681728	usd
CY2022Q3	us-gaap	Goodwill Goodwill	15388546	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	27195000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-320000	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26875000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	27195000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	27195000	usd
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1071965	shares
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	10432641	usd
	CODX	Contingent Considered Issued For Measurement Period Adjustments ContingentConsideredIssuedForMeasurementPeriodAdjustments	199359	usd
	CODX	Contingent Considered Issued For Business Acquisitions ContingentConsideredIssuedForBusinessAcquisitions	-7079446	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3552554	usd
CY2021Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1011333	shares
	us-gaap	Net Income Loss NetIncomeLoss	7667231	usd
	us-gaap	Net Income Loss NetIncomeLoss	29160154	usd
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	893326	shares
CY2022Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y3M18D
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5094456	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	30101353	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	32816726	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	77484262	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	150000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	150000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1361062	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	11475966	usd
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31321368	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29952690	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33002539	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29872415	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.40
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.01
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.38
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.23
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.98
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2631642	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1385869	shares
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	147436	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1111363	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.12
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.31
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M13D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	70791	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.10
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised	0.51
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1040572	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.19
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.37
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P6Y1M17D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1040572	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.19
CY2022Q3	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable	1.37
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M17D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	526281	shares
CY2021Q4	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	8.15
CY2021Q4	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue	4.01
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1	P4Y8M12D
	CODX	Share Based Compensation Issued For Adjustments To Contingent Purchase Consideration ShareBasedCompensationIssuedForAdjustmentsToContingentPurchaseConsideration	8719	shares
	CODX	Issued For Adjustments To Contingent Purchase Consideration Period Weighted Average Exercise Price IssuedForAdjustmentsToContingentPurchaseConsiderationPeriodWeightedAverageExercisePrice	9.13
	CODX	Issued For Adjustments To Contingent Purchase Consideration Weighted Average Grant Date Fair Value IssuedForAdjustmentsToContingentPurchaseConsiderationWeightedAverageGrantDateFairValue	1.88
	CODX	Issued For Adjustments To Contingent Purchase Consideration Weighted Average Remaining Contractual Term1 IssuedForAdjustmentsToContingentPurchaseConsiderationWeightedAverageRemainingContractualTerm1	P4Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	50000	shares
	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice	2.00
	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	1.22
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	485000	shares
CY2022Q3	CODX	Share Based Compensation Arrangement By Share Based Payment Award Options Non Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice	8.81
CY2022Q3	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	2.43
	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3	P4Y3M18D
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2230434	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1410945	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5138815	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3851293	usd
CY2022Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.438	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.300	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2100594	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6231310	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	82797	usd
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	50774	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	253748	usd
CY2022Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	113294	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	277454	usd
CY2022Q3	us-gaap	Lease Cost LeaseCost	196091	usd
	us-gaap	Lease Cost LeaseCost	531202	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	73783	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	303059	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	50773	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	427615	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8799	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	418816	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	292536	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	126280	usd
CY2022Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	192659	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	514009	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.031	pure
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.031	pure
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	293595	usd
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	303059	usd
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	647428	usd
CY2022Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	30000000.0	usd
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	-0	shares
	CODX	Repurchases Of Common Stock RepurchasesOfCommonStock	3414326	shares
CY2022Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	3414326	shares

Files In Submission

Name	View Source	Status
0001493152-22-031350-index-headers.html	Edgar Link	pending
0001493152-22-031350-index.html	Edgar Link	pending
0001493152-22-031350.txt	Edgar Link	pending
0001493152-22-031350-xbrl.zip	Edgar Link	pending
codx-20220930.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
codx-20220930_def.xml	Edgar Link	unprocessable
codx-20220930_lab.xml	Edgar Link	unprocessable
codx-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
codx-20220930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CODX
Co-Diagnostics Inc Stock $codx

2022 Q4 Form 10-Q Financial Statement

#000149315222031350 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CODX Co-Diagnostics Inc Stock $codx

2022 Q4 Form 10-Q Financial Statement

#000149315222031350 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CODX
Co-Diagnostics Inc Stock $codx